BMY Share Price

Open 55.55 Change Price %
High 55.68 1 Day -0.79 -1.41
Low 54.36 1 Week -0.56 -1.00
Close 55.24 1 Month 2.08 3.91
Volume 12151500 1 Year -14.16 -20.40
52 Week High 77.12
52 Week Low 49.03
BMY Important Levels
Resistance 2 56.46
Resistance 1 55.96
Pivot 55.09
Support 1 54.52
Support 2 54.02
NYSE USA Most Active Stocks
BAC 22.57 1.85%
BAC 22.57 1.85%
BAC 22.57 1.85%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
CHK 7.58 0.00%
More..
NYSE USA Top Gainers Stocks
IPI 2.49 36.81%
IPI 2.49 36.81%
IPI 2.49 36.81%
POM 26.93 26.79%
POM 26.93 26.79%
VRS 6.20 15.24%
VRS 6.20 15.24%
CVI 21.14 14.33%
SAB 7.20 12.50%
SAB 7.20 12.50%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
OIBR 0.17 -43.33%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Bristol-Myers Squibb Company (NYSE: BMY)

BMY Technical Analysis 1.5
As on 7th Dec 2016 BMY Share Price closed @ 55.24 and we RECOMMEND Sell for LONG-TERM with Stoploss of 63.45 & Buy for SHORT-TERM with Stoploss of 53.72 we also expect STOCK to react on Following IMPORTANT LEVELS.
BMY Target for December
1st Target up-side 60.5
2nd Target up-side 63.35
3rd Target up-side 66.19
1st Target down-side 52.38
2nd Target down-side 49.53
3rd Target down-side 46.69
BMY Other Details
Segment EQ
Market Capital 54918418432.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.bms.com
BMY Address
BMY
345 Park Avenue
New York, NY 10154
United States
Phone: 212-546-4000
Fax: 212-546-4020
Interactive Technical Analysis Chart Bristol-Myers Squibb Company ( BMY NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Bristol-Myers Squibb Company
BMY Business Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.